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Introduction
Approximately 171 million people worldwide have diabetes, 
and this number is increasing.1 Diabetes mellitus is a 
chronic illness, characterised by hyperglycaemia resulting 
from impairments in insulin secretion, defects in insulin 
action, or both. The classification of diabetes has moved 
away from a system where the disease was distinguished 
based on the requirement for insulin therapy, to one based 
on the pathogenesis of the disease, wherever possible (see 
Table I). 
The correct classification is important because of the 
different therapeutic options available to treat the different 
forms of diabetes. Worldwide, the incidence of type 1 
diabetes is increasing, with more children being obese on 
presentation as a result of the escalating prevalence of 
obesity in the youth.3 In addition, there is an epidemic of type 
2 diabetes in adolescents.4 Clinical distinction is difficult, 
not only because of the overlap in clinical presentation 
between obese type 2 diabetic patients and obese children 
with type 1 diabetes, but also as a result of other forms 
of diabetes present in the age group < 45 years [maturity 
onset diabetes in the young (MODY) and latent autoimmune 
diabetes in adults (LADA)]. An educated decision regarding 
the type of diabetes can be made based on family history 
and laboratory tests, including tests for autoimmune 
markers. However, these types of tests are expensive, and 
are not readily available in resource-poor African countries. 
A number of autoantibodies, genes and environmental factors 
have been shown to be associated with type 1 diabetes. 
Worldwide, these risk factors have been extensively studied 
to differentiate type 1 diabetes from other forms of diabetes. 
The question arises as to whether or not the genetic and 
autoimmune associations seen in the rest of the world 
hold true in African type 1 diabetics. In South Africa, and 
Africa in general, there is sparse information regarding the 
epidemiology of this disease, and it is poorly characterised 
in the black population. This review will provide an overview 
of the epidemiological, immunological and genetic data that 
have been generated on type 1 diabetes in Africa, especially 
in the black population.
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Abstract
Type 1 diabetes is a serious, debilitating disease, with life-threatening complications, and the financial burden associated 
with the management of this disease is enormous. Early diagnosis and intervention can improve morbidity and mortality. 
Unfortunately, in Africa, type 1 diabetes is poorly characterised, and there is sparse information regarding the aetiology and 
epidemiology of this disease. However, there is some evidence of a later age of onset in African type 1 diabetic patients, 
compared to European diabetics, and it is thought that the prevalence of type 1 diabetes is lower in African populations than 
in the Western world.
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Table I: Aetiological classification of diabetes mellitus2
Diabetes mellitus
Type 1 diabetes (b cell destruction, usually leading to absolute insulin 
deficiency)
•	 Autoimmune (type 1A)
•	 Idiopathic (type 1B)
Type 2 diabetes (results from a progressive insulin secretory defect on 
the background of insulin resistance)
Other specific types of diabetes, e.g. genetic defects of b cell function 
or insulin action, diseases of the exocrine pancreas, or drug- or 
chemical-induced diabetics
Gestational diabetes (diagnosed during pregnancy)
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Type 1 diabetes mellitus
Type 1 diabetes is caused by the autoimmune destruction 
of the insulin-producing b cells of the pancreas.5 The 
destruction process is marked by infiltration of the 
pancreatic islets by mononuclear cells, and may take place 
over a period of many years.6 A large proportion (> 80%) 
of the b cells are destroyed by the time clinical symptoms 
appear.7
In 2000, it was estimated that 171 million adults 20 years of 
age or older have diabetes.1 Type 1 diabetes accounts for 
5-10% of all cases of the disease. The majority of patients 
(approximately 40%) are diagnosed and classified with type 
1 diabetes within the first two decades of life, making it one 
of the most common severe chronic diseases of childhood. 
However, an increasing number of cases are being 
recognised in older individuals. In the USA, 1:300 children, 
and as many as 1:100 adults, develop this disease.8
There is a large geographical variability in the incidence 
of type 1 diabetes.9 Scandinavia (36.5/100 000 per year in 
Finland) and the Mediterranean island of Sardinia (36.8/100 
000 per year) have the highest incidence rates in the world, 
while Oriental populations have the lowest rates (0.1/100 
000 per year in China).10 There are few articles in the 
literature reporting the incidence and prevalence of type 1 
diabetes in Africa. Table II summarises the data obtained 
from African countries.
The incidence of type 1 diabetes changes with age. The 
incidence increases from birth to 12 years, reaching a peak 
at 10-14 years of age, before falling to a much lower rate.22 
Studies conducted among African populations have shown 
a peak incidence of type 1 diabetes at 20-29 years of age, 
which is a decade later than that observed in Caucasian 
populations.12,23 The reasons for this later age of onset in 
Africans are not known.
In most instances, there is no difference in the incidence 
of type 1 diabetes in males and females, with the pubertal 
peak of incidence in females preceding that in males by 
one to two years.24 In Africa, there seem to be conflicting 
reports regarding the gender ratios of black patients with 
type 1 diabetes (see Table II). Studies carried out among 
Ethiopian and Nigerian type 1 diabetes patients found a 
two- and threefold higher incidence of type 1 diabetes in 
males compared to females, respectively.12,16 In contrast, 
a study carried out among black South African type 1 
diabetics, and a second study on Sudanese patients, 
found a slightly higher incidence of female to male patients, 
although this was not statistically significant.18,19,23 A female 
predominance was shown in Libyan type 1 diabetic patients 
in the age range 0-14 years, but a male predominance in the 
age group 15-34 years. When all the patients were taken as 
a whole, there was a male predominance in the incidence of 
type 1 diabetes.15
Table II: The prevalence/incidence of type 1 diabetes in Africa
 Prevalence Incidence Male:female ratio Age range
Algeria 0.27/1 00011 8.1/100 00011 < 20 years
Ethiopia 2.1/100 00012 Twice as high in males as in females 0-78 years, with a peak incidence at 25-29 years
Ghana 0.75/1 00013
Libya 7.8/100 00014 Excess risk for females vs. males 0-14 years
9/100 00015 Increased incidence of male to female. 
Female predominance in group aged 
0-14 years, male predominance in 
group aged 15-34 years.
< 35 years
Nigerian Igbo 0.25-0.46/1 00016 3:1 male:female prevalence ratio 5-17 years
North-West Nigeria 3.1/1 00017 1:0.6 male:female ratio Age at presentation: 10 ± 4.5 years
Sudan 10.1/100 00018 Slightly higher in females than males 0-14 years. Peaks at 12 and 14 years in females 
and males, respectively
0.95/1 00019 Slightly higher in females than males 7-14 years
Tanzania 1.5/100 00020 0-19 years. Incidence increased with age
Tunisia 6.76/100 00021 No difference 0-14 years. Incidence peaked in group  
aged 10-14 years.  
6.95/100 00021 No difference 0-19 years
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Autoimmunity
Autoantibodies in type 1 diabetes
Autoantibodies are currently the most frequently used 
markers for the prediction of type 1 diabetes. The most 
prevalent autoantibodies are directed at the 65 kDa isoform 
of glutamic acid decarboxylase (GAD65; 70-80%), the 
tyrosine phosphatase-like protein (IA)-2 (50-80%), and 
insulin (IAA; ± 50% in newly-diagnosed children).25-27 Up 
to 90% of newly diagnosed type 1 diabetic patients have 
autoantibodies to one or more of these autoantigens. The 
percentage positivity depends on the age and ethnicity of 
the patient, as well as the duration of the disease. These 
autoantibodies can be present in the serum of prediabetic 
individuals years before clinical diagnosis, and the presence 
of all three autoantibodies is highly predictive of future type 
1 diabetes development.28
There are very limited epidemiological, immunological 
and genetic data available for the African type 1 diabetes 
population, especially in southern Africa. Over the past 
30 years, there have been approximately 15 publications, 
the majority from northern Africa, reporting on the presence 
of autoantibodies in the serum of African type 1 diabetic 
patients. The majority of papers have only addressed the 
presence of islet cell antibodies (ICAs). 
As seen in Table III, there is wide variation in the frequency 
of ICAs within Africa.29-36 The observed frequencies are 
lower than those reported in Caucasian type 1 diabetic 
populations.37 Less than a third of the publications 
considered the presence of two or more autoantibodies. 
The prevalence of GAD autoantibodies was studied in 84 
Tunisian type 1 diabetic children.36 With increasing duration 
of type 1 diabetes, the prevalence of GAD autoantibodies 
decreased: 84.6% of children with newly-diagnosed 
diabetes (< 6 months) were positive for GAD autoantibodies, 
as opposed to only 29.41% in those with a longer duration 
of disease (> 5 years). In another study, 47 type 1 diabetes 
patients from Cameroon were screened for GAD and IA-2 
autoantibodies.38 The mean disease duration was 3.3 years. 
Sixteen patients and three patients were GAD- and IA2-
autoantibody-positive, respectively. Similarly, a study carried 
out in Tanzania revealed lower frequencies of GAD and IA-2 
autoantibodies compared to Caucasian type 1 diabetic 
patients.37,39 Only one paper looked at the frequency of all 
four autoantibodies in 86 newly diagnosed type 1 diabetic 
children from Tunisia.31 The authors found that 78 (90.7%) 
children were positive for one or more autoantibody. Only 
three papers were identified that reported the screening of 
black South Africans for the presence of disease-associated 
autoantibodies. In the first paper, ICAs were found in over 
a third of black and Indian South African patients.40 The 
Table III: The prevalence of type 1 diabetes associated autoantibodies in African populations
Study population Number and type of patients ICA+ GAD65+ IA-2+ IAA+
Ethiopia29 43 newly diagnosed black 39% - - -
Tunisia30 175 black 45.1% - - -
Tunisia31 86 newly diagnosed black 57% 65.1% 43% 50%
Sudan32 46 newly diagnosed black 63% - - -
Sudan33 96 black 41.7% - - -
Nigeria34 68 black 5.9% - - -
Tanzania35 35 newly presenting black 8.6% - - -
Tunisia36 84 black 21.4% 51.2% - -
Cameroon38 47 black - 34% 6.4% -
Tanzania39 94 black - 21.3% 12.8%
South Africa40 47 black 36.2% - - -
34 Indian 32.4% - - -
South Africa41 100 black - 44% - -
South Africa42 43 black - 33% - -
17 Caucasian - 67% - -
America37 113 black 58% 54% 38% 20%
117 Caucasian 77% 73% 65% 35%
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remaining two studies examined the presence of GAD 
autoantibodies, and found a lower prevalence in black type 
1 diabetic patients, compared to Caucasian type 1 diabetic 
patients.41,42
Autoantibodies and latent autoimmune diabetes in 
adults
GAD65 and insulin autoantibodies were also found in 5-10% 
of patients classified with type 2 diabetes.43,44 Initially, these 
patients have residual b cell function, sufficient to prevent 
the development of acute metabolic decompensation 
(ketosis) for many years. However, the b cell mass declines 
over time, thus necessitating insulin treatment.45 This slowly 
progressing form of type 1 diabetes is termed LADA, or type 
1.5 diabetes.44,46 The Immunology of Diabetes Society has 
proposed the following definition for LADA: patients must be 
≥ 30 years of age, be positive for at least one autoantibody, 
and require no insulin within the first six months following 
diagnosis.
There is sparse information on the presence or absence of 
LADA in Africa. One reason for this may be the difficulty 
in classifying the different types of diabetes. In a study 
conducted in 124 type 2 diabetic patients from Nairobi, it 
was found that 79% were “true” type 2, 5.7% were LADA, 
12.1% were type 1B, and 3.2% were type 1A diabetics.47 
Similar findings were reported in a study of 103 non-insulin-
requiring diabetic patients from Ghana.13 Seventeen (16.5%) 
of the non-insulin-requiring patients were positive for ICA 
and/or GAD and/or IAA, and the prevalence of LADA in this 
group was 13.5%.13 Thus, clinical judgement alone cannot 
be used to classify patients, and may be one of the reasons 
for the poor glycaemic control seen in a number of diabetic 
patients.
Susceptibility to type 1 diabetes mellitus
The rapid increase in the incidence of type 1 diabetes 
(3.9% average annual increase in Europe over the period 
1989-2003) cannot be accounted for by genetics alone.48 A 
seasonal variation in the incidence of type 1 diabetes has 
been observed. There is a decline during the warm summer 
months.49 However, this seasonal pattern only appears 
to occur in older children and adolescents, suggesting 
that factors triggering diabetes may be related to school 
attendance or viral infections.50
In Africa, as in the rest of the world, there are confounding 
reports as to whether or not viruses are a significant factor 
in the aetiology of type 1 diabetes. A study of 40 insulin-
treated Nigerian diabetics did not show any association 
of Coxsackie B1, mumps, rubella and enterovirus group 
antigen with type 1 diabetes. The non-diabetic control 
samples (who were matched for age, sex and social 
status) had significantly higher levels of Coxsackie A virus 
compared to the diabetic patients.51 Thus, in this group, 
previous exposure to these viruses is not a trigger of type 1 
diabetes. A second study conducted on 40 newly diagnosed 
type 1 diabetic patients (> 1-year duration of disease; Group 
1), 30 type 1 diabetic patients (< 1-year duration; Group 2) 
and 30 healthy non-diabetic children from Egypt showed 
a significant increase in the evidence of viral infection in 
Group 1 and Group 2 vs. the control subjects.52
Genetic susceptibility
Type 1 diabetes is a heterogeneous and polygenic disorder. 
There are currently more than 40 gene loci that have 
been linked with influencing type 1 diabetes risk. The two 
major susceptibility regions that have been identified are 
IDDM1, the major histocompatibility complex region on 
chromosome 6p21, and IDDM2, the insulin gene region on 
chromosome 11p15.5.53
The best studied is IDDM1, which contains the human 
leucocyte antigen (HLA) genes that code for HLA class II 
antigens. Fine mapping of this locus suggests that two HLA 
haplotypes, DR3 and DR4, are strongly associated with 
type 1 diabetes susceptibility.54 The vast majority (90%) of 
type 1 diabetics have either DR3,DQ2 (DQ2 = DQA1*0501, 
DQB1*0201) or DR4,DQ8 (DQ8 = DQA1*0301, DQB1*0302) 
haplotypes, whereas 40-50% of most non-diabetics have 
one or the other of these haplotypes. Between 30-50% 
of patients with type 1 diabetes are heterozygotes with 
DR3,DQ2/DR4,DQ8 compared with only 2.4% of the 
general population.
A number of studies have analysed the frequency of HLA 
antigens in African type 1 diabetic patients. One study 
conducted in Algerian type 1 diabetic patients found a 
strong association of DR3 with type 1 diabetes. DR4 was 
found to be equally distributed in patients and controls 
(21% vs. 28.4%). However, the DR3 and DR4 heterozygous 
allele was present more frequently in diabetics.55 A second 
study found a higher frequency of the haplotypes (DR3DQ2 
or DR4DQ8) in diabetics (85%) vs. controls (34%), and 42% 
of the patients had the heterozygous haplotype DR3DQ2/
DR4DQ8.56 A third study carried out in western Algeria, 
where there is a high rate of consanguineous marriages, 
failed to show an association of DR3 with diabetes, but 
there was an association with DR4 and DR3/DR4 antigens.57
Several studies have been performed on the diabetic 
population of Tunisia. All studies showed a positive 
association with DR3 and DR4, and a strong association 
of the heterozygote genotype DR4-DQw8/DR3-DQw2 to 
type 1 diabetes.58-60 DR2 and DR5 were confirmed to play 
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a protective role in this population group.58 Similarly, Abid 
Kamoun et al have shown the DRB1*01501 DQB1*0602 and 
DRB1*11 DQB1*0301 haplotypes to be protective.60
The majority of studies that have focused on the HLA 
antigens (typed serologically) have been carried out in 
South Africa. In the first study, conducted in 1980, Briggs et 
al, found no increase in the frequency of B8 and B15, and 
no decrease in B7 in the 25 Xhosa type 1 diabetic patients.61 
This is in contrast to what was observed in Caucasian type 1 
diabetic patients. Hammond et al did find an increase in the 
frequency of B8 and B14 in 57 black South African diabetic 
patients.62 In 1983, Shires et al compared the frequency of 
HLA antigens in 72 Caucasian, and 53 black, type 1 diabetic 
patients.63 HLA A1 and B8 antigens were significantly 
increased, while A3 and B17 antigens were reduced in the 
Caucasian diabetic group. Only HLA B8 was increased in 
the black diabetic sample. Two studies were conducted by 
Omar et al, in which the HLA A, B and C antigen status 
were determined, in addition to DR typing, in black and 
Indian type 1 diabetic patients from South Africa.64,65 In 
the black patients, the frequency of DR4 was significantly 
higher compared to in the control subjects, and DR3/DR4 
heterozygosity was associated with a greater relative risk 
for developing disease, compared to the presence of DR3 
alone. Indian diabetic patients showed a significant increase 
in the frequency of B8, Aw24 and DR3 HLA antigens, 
compared to controls. A strong association was also 
observed with DR4 among patients of north Indian origin. 
A study conducted on black South African and coloured 
South African type 1 diabetic patients, showed a weak 
association with DRw9 in the black population, but failed 
to show any other associations commonly seen in black 
American type 1 diabetic patients. The coloured patients 
failed to show an association with B8 and DR3, but did have 
an increased frequency of DR4 and a decreased frequency 
of DR2, commonly seen in Caucasian populations.66 
The latest South African study reported in the literature was 
published in 2001. In this study, Zulu diabetics [typed by 
polymerase chain reaction (PCR) with sequence-specific 
primers] showed the presence of the common susceptibility 
antigens: DR3, DR4, DQ2 and DR9.67 These findings were 
similar to those reported from other studies. One study 
carried out in Nigeria did not show an association of type 
1 diabetes with DR4. The reason for this may be that DR4 
correlates with an early age of onset in Caucasian type 1 
diabetic patients, and the Nigerian patients in this study had 
an age of onset > 20 years.68
Although susceptibility to type 1 diabetes is strongly 
associated with certain HLA alleles, other genetic loci also 
play a role in the triggering and/or development of the 
disease. The IDDM2 locus accounts for about 10% of the 
susceptibility toward type 1 diabetes.69 This locus maps to a 
variable number of tandem repeats (VNTR), or minisatellites, 
upstream of the insulin gene.53 The short class I VNTRs 
(30-44 repeats) predominate (70%) in Caucasians. The 
remaining alleles tend to fall into the longer class III category. 
The intermediate lengths (class II) are rare. Class I VNTR 
alleles predispose to type 1 diabetes, whereas the class III 
alleles have a dominant protective effect.69 The presence 
of at least one class III allele is associated with a threefold 
reduction in the risk of developing type 1 diabetes.70
Undlien et al studied 488 type 1 diabetics from three different 
ethnic groups, Tanzanian blacks, Norwegian Caucasians 
and Japanese Orientals, to determine whether there was 
an association between polymorphisms in the insulin gene 
and the occurrence of type 1 diabetes.71 The presence of 
insulin gene polymorphisms conferred susceptibility in the 
Caucasian patients, as well as the Tanzanians. However, this 
tendency was not statistically significant. No association 
was observed in the Japanese population group.
Findings of the majority of genetic studies conducted in 
Africa are in agreement with those from studies carried 
out in Europe and America, namely that DR3 and DR4 are 
more common in type 1 diabetic patients, and that the 
heterozygote haplotype, DR3/DR4, is strongly associated 
with type 1 diabetes. A number of studies also support 
the protective role of DR2 and DQB6. There are also some 
haplotypes that are unique to different regions in Africa. 
Larger studies are required among African populations to 
determine which haplotypes are suggestive of an increased 
risk of type 1 diabetes development in the different ethnic 
groups. Similarly, an insufficient number of studies have 
been carried out to determine whether or not there is an 
association between the different susceptibility genes and 
type 1 diabetes in Africa.
Conclusion
Little is known about the autoimmune role in the pathology 
of disease in African populations. One study has shown 
a lower prevalence of GAD autoantibodies in black South 
Africans, compared to data obtained from Caucasian type 
I diabetic patients.42 There is some evidence of ethnic 
differences in the autoimmune response. This needs to be 
further investigated, using the measurement of GAD, IA-2 
and insulin autoantibodies. The latter two autoantibodies 
have never been investigated in the South African black 
population. 
It should also be borne in mind that the prevalence of type 1 
diabetes is thought to be lower in Africans than Europeans. 
Therefore, there may also be significant ethnic differences 
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in both the aetiology and pathology of the disease.72 Further 
research into the aetiology and pathology of type 1 diabetes 
in Africa needs to be conducted, as the information will help 
to characterise diabetes in the different population groups. 
This will provide important information on the role of the 
immune system in the disease aetiology, particularly in 
black Africans, for whom there are currently little such data.
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